Active, not recruitingPhase 2NCT04195139

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Studying Astrocytoma

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Sydney
Principal Investigator: Mustafa Khasraw
Duke University
Intervention: Nivolumab(drug)
Enrollment: 103 target
Eligibility: 65 years · All sexes
Timeline: 2018 – 2025

Study locations (20)

Duke University Medical Center, Durham, North Carolina, United States
Campbelltown Hospital, Campbelltown, New South Wales, Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Gosford Hospital, Gosford, New South Wales, Australia
Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia
Port Macquarie Hospital, Port Macquarie, New South Wales, Australia
Prince of Wales Hospital, Randwick, New South Wales, Australia
Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
Wollongong Hospital, Wollongong, New South Wales, Australia
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
Icon Cancer Centre, South Brisbane, Queensland, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Flinders Medical Centre, Bedford Park, South Australia, Australia
Royal Hobart Hospital, Hobart, Tasmania, Australia
+5 more locations on ClinicalTrials.gov

Collaborators

Cooperative Trials Group for Neuro-Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04195139 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma →

← Back to all trials